Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Serina Therapeutics ( (SER) ) just unveiled an update.
On January 14, 2025, Serina Therapeutics announced the appointment of Karen J. Wilson to its Board of Directors, marking a significant addition due to her extensive experience in the life sciences sector. Wilson’s financial and industry expertise is expected to support Serina’s strategic initiatives and enhance its positioning in the biotechnology market. Concurrently, Steven Mintz departed from the board, with Remy Gross taking over as the chair of the Audit Committee.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, focusing on developing drug product candidates to treat neurological diseases and other indications. Their proprietary POZ Platform™ is used to enhance drug delivery, offering potential improvements in efficacy and safety for small molecules, RNA-based therapeutics, and antibody-drug conjugates. The company is also exploring partnerships to expand the applications of its POZ technology.
YTD Price Performance: -3.92%
Average Trading Volume: 26,931
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $43.57M
See more insights into SER stock on TipRanks’ Stock Analysis page.